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The use of hormonal contraception is associated with an increased risk of venous thromboembolism (VTE). Unfavorably altered
fibrin clot phenotype has been reported in patients following unprovoked VTE who are at risk of recurrences. It remains
unknown whether fibrin clot characteristics in women with contraception-related VTE differ from those in unprovoked VTE.
We studied three age-matched groups of women: (1) after contraception-related VTE, (n = 48) (2) after unprovoked VTE
(n = 48), and (3) controls (n = 48). Plasma fibrin clot permeability (Ks), turbidity of clot formation, efficiency of fibrinolysis
using clot lysis time (CLT), and rate of increase in D-dimer during lytic clot degradation (D-Drate), along with thrombin
generation and fibrinolysis proteins were determined. Compared with the controls, patients following contraception-related and
unprovoked VTE formed faster (lag phase, -8.8% and -20.4%, respectively) fibrin clots of increased density (Ks , -8.6% and -13.4%,
respectively) displaying impaired fibrinolysis as evidenced by prolonged CLT (+11.5% and +14.5%, respectively) and lower
D-Drate (-7.1% and -5.6%, respectively), accompanied with higher plasminogen activator inhibitor-1 (PAI-1, +14.9% and +17.8%,
respectively) and elevated peak thrombin generation (+63.8% and +36.7%, respectively). The only differences between women
with unprovoked and contraception-related VTE were lower fibrin mass in plasma clots (D-Dmax, -8.6%), along with higher peak
thrombin generation (+19.8%) and shorter lag phase (-6.8%) in the latter group. This study suggests that women after
contraception-related VTE, similar to those following unprovoked VTE, have denser fibrin clot formation and impaired clot lysis.
These findings might imply higher risk of VTE recurrence in women with the prothrombotic clot phenotype.
1. Introduction
Venous thromboembolism (VTE), including both pulmo-
nary embolism (PE) and deep vein thrombosis (DVT), is a
rare complication of combined hormonal contraceptives
(CHCs) with the annual incidence of 7-12 events per
10,000 women [1, 2]. The risk of VTE may vary depending
on estrogen dose, formula, and types of progestogens [3, 4].
Both hormones lead to a procoagulant risk profile associated
with higher plasma D-dimer, tissue plasminogen activator
(tPA), and coagulation factors II, VII, and X [5, 6]. Moreover,
CHCs diminish levels of the natural anticoagulants such as
protein C and antithrombin and may lead to the resistance
to activated protein C [4].
The prothrombotic fibrin clot phenotype denotes forma-
tion of stiff fibrin clots composed of compact fiber networks
displaying decreased porosity, expressed by low clot perme-
ability coefficient (Ks), and resistance to plasmin-mediated
lysis reflected by, e.g., prolonged clot lysis time (CLT) [7].
Unfavorably altered fibrin clot properties have been shown
to increase the risk of unprovoked VTE and recurrent PE
as well as DVT [8–10].
There is a controversy whether the first contraception-
related VTE can be classified as either unprovoked VTE,
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implicating that hormonal therapy is a “weak” risk factor, or
provoked VTE with a known risk factor [11, 12]. Impor-
tantly, considering the risks and consequences of long-term
anticoagulation, it is necessary to determine if women devel-
oping VTE on CHCs should be managed as patients with
unprovoked or provoked VTE. Current guidelines recom-
mend an anticoagulant therapy for a minimum of 3 months
in both provoked and unprovoked VTE [13]. The extended
anticoagulant therapy should also be considered in women
with contraception-related VTE [14].
Women with contraception-related VTE have been
found to display a mild prothrombotic fibrin clot phenotype,
reflected by faster formation of dense meshwork (reflected by
lower Ks values) which is relatively resistant to plasmin-
induced lysis [4, 7]. Analysis of VTE patients showed that
women with both prolonged CLT and hypofibrinolysis
resulting from oral contraceptive usage have a 20-fold
increase in the VTE risk when compared with individuals
with the shorter CLT and without this risk factor [15].
We hypothesized that unfavorably altered clot character-
istics occur in women following contraception-related VTE
compared with well-matched control and the plasma fibrin
clot phenotype is less prothrombotic than in well-matched
women after unprovoked VTE.
2. Materials and Methods
2.1. Participants. In this case-control study, we enrolled
48 consecutive women with a history of the first
contraception-related VTE for further work-up in the Center
for Coagulation Disorders in Kraków, Poland, from July 2014
to June 2016.
Women who took various agents containing ethinylestra-
diol in combination with levonorgestrel or gestoden when
taken orally or in combination with norelgestromin when
used transdermally, at the time of VTE diagnosis, were eligi-
ble. Women who used contraceptives for indication other
than the prevention of pregnancy such as endometriosis,
polycystic ovary syndrome, and intermenstrual bleeding
were ineligible. All women after VTE occurrence stopped
taking hormonal contraception.
Patients were eligible if DVT and/or PE diagnosed on
oral or transdermal contraceptives were treated for at least
3 months. Exclusion criteria were age above 50 years,
recurrent thrombotic event, ischemic heart disease, valvu-
lar heart disease, severe hypertension, diabetes with vascu-
lar involvement, and the presence of known VTE risk
factors, including recent major surgery with prolonged
immobilization or trauma, deficiency of antithrombin, pro-
tein C or protein S, antiphospholipid syndrome, acute cor-
onary syndrome or ischemic stroke within the previous 3
months, known malignancy, any chronic inflammatory
diseases (e.g., rheumatoid arthritis) or signs of an acute
infection, advanced chronic renal disease (estimated glo-
merular filtration rate (eGFR) <30mL/min), and interna-
tional normalized ratio (INR) more than 1.2 at the day
of blood draw and pregnancy.
We collected data on risk factors and comorbidities.
Smoking was defined as the daily use of 1 or more cigarettes.
Family history of VTE was specified as a VTE episode in a
first-degree relative documented in medical records includ-
ing imaging examination. Arterial hypertension was defined
as a systolic blood pressure of 140mmHg or higher or a dia-
stolic blood pressure of 90mmHg or higher, or taking an
antihypertensive medication. Obesity is defined as having a
body mass index (BMI) of 30 kg/m2 or greater. Diabetes mel-
litus was defined in accordance with the American Diabetic
Association Criteria.
At the same time, we recruited two groups matched for
age by frequency (48 women in each group):
(1) The unprovoked VTE group of women with no
knownmalignancy, major trauma within 6 preceding
weeks or surgery requiring general anesthesia, with-
out prior use of oral contraceptive or hormone
replacement therapy, and no pregnancy or delivery
within the last 3 months
(2) The no-VTE control group comprising women free
of documented VTE; subjects with mild arterial
hypertension or diabetes mellitus without medication
were also eligible
DVT was diagnosed based on symptoms and docu-
mented using color duplex sonography (visualization of an
intraluminal thrombus either in the calf, popliteal, femoral,
or in iliac veins). The diagnosis of PE was based on the pres-
ence of characteristic symptoms and positive results of high-
resolution spiral computed tomography. All women with
VTE were treated with low-molecular-weight heparins
(LMWH) at therapeutic doses for 2-10 days followed by
non-vitamin K antagonist oral anticoagulants (NOAC).
The Bioethical committee approved the study and all
subjects signed written consents.
2.2. Laboratory Investigations. Venous blood samples were
drawn with minimal stasis using atraumatic venipuncture
at 08.00–11.0 AM, after an overnight fast. All measurements
were performed in VTE patients after 3 months of anticoag-
ulant therapy since the index event. Patients were drawn >24
hours since the last dose of NOACs. Complete blood count,
glucose, creatinine, lipid profiles, and INR were assayed by
routine laboratory techniques. High-sensitivity C-reactive
protein (hs-CRP) was determined by immunoturbidimetry
(Roche Diagnostics GmbH, Mannheim, Germany). Plasma
D-dimer was measured with the Innovance D-dimer assay
(Siemens, Marburg, Germany). Plasma α2-antiplasmin and
plasminogen were measured by chromogenic assays (STA
Stachrom antiplasmin and Stachrom plasminogen, Diagnos-
tica Stago, Asniéres, France). Plasma PAI-1 antigen was mea-
sured by an ELISA kit (Hyphen). For evaluation of clot
properties and thrombin generation, venous blood samples
were mixed with 3.2% trisodium citrate (vol/vol, 9 : 1), then
centrifuged at 2000× g for 10min within 30 minutes of the
draw, and stored in aliquots at -80°C until analysis. All mea-
surements were performed by technicians blinded to the ori-
gin of the samples. Intra-assay and interassay coefficients of
variation were 5-7%.
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2.3. Thrombin Generation.Calibrated automated thrombogra-
phy (CAT) (Thrombinoscope BV, Maastricht, Netherlands)
were used to assess peak thrombin concentration, using in a
96-well plate fluorometer (Ascent Reader, Thermolab
Systems OY, Helsinki, Finland) at 37°C according to the
manufacturer’s instructions, as previously described [16].
Briefly, platelet-poor plasma (80μL) was diluted with a tissue
factor (TF; 20μL)-based activator (Diagnostica Stago,
Asniéres, France) containing recombinant TF (5 pML-1),
phosphatidylserine/phosphatidylcholine/phosphatidyletha-
nolamine vesicles (4 micromolar) and FluCa solution
(Hepes, pH7.35, 20μL of 100 nML-1 CaCl2, 60mgmL-1
bovine albumin, and 2.5mML-1 Z-Gly-Gly-Arg-amidome-
tylcoumarin). The maximum concentration of thrombin
formed during the time of registration was described as the
thrombin peak, and the area under the curve represented
ETP. The peak thrombin level was analyzed twice.
2.4. Fibrin Permeation. Fibrin clot permeation was deter-
mined using a pressure-driven system as described [17].
Briefly, calcium chloride (20mmol L-1) and human thrombin
(Sigma, St. Louis, MO, USA; 1UmL-1) were added to a
citrated plasma (120μL). After incubation in a wet chamber,
tubes containing the clots were connected via plastic tubing
to a reservoir of a buffer (0.01M Tris, 0.1M NaCl, pH7.4)
and its volume flowing through the gels was measured within
60min.
A permeation coefficient (Ks), which indicates the pore
size, was calculated from the equation:
Ks =
L ⋅ η ⋅Q
t ⋅ A ⋅ Δp
, ð1Þ
where Q is the flow rate in time t; L, the length of a fibrin gel;
μ, the viscosity of liquid (in poise);A, the cross-sectional area
(in cm2); Δp, a differential pressure (in dyne cm-2); and t, the
percolating time.
2.5. Turbidity Measurements. Clot formation was assessed as
previously described [15]. Briefly, plasma-citrated samples
were mixed 2 : 1 with a Tris buffer, containing human throm-
bin (Sigma; 0.6U/mL) and calcium chloride (50mM), which
initiated polymerization.
Both the lag phase of the turbidity curve, which show the
time required for initial protofibril formation, and maximum
absorbance at the plateau phase (ΔAbsmax), indicating the
number of protofibrils per fiber, were recorded. Absorbance
was read at 405nm.
2.6. Lysis Assays.Clot lysis time was assessed using two differ-
ent methods, as previously described [18]. Briefly, CLT was
measured in the essay in which citrated plasma was mixed
with calcium chloride (15mmol L-1), 10,000-diluted human
TF (Innovin, Siemens) with a final concentration of phos-
pholipid vesicles (0.6 pM, 12μM), and rtPA (60ng/mL;
Boehringer Ingelheim, Ingelheim, Germany). The turbidity
was measured at 405 nm at 37°C. CLT was defined as the time
from the midpoint of the clear-to-maximum-turbid transi-
tion, which reflects clot formation, to the midpoint of the
maximum-turbid-to-clear transition. To measure clot degra-
dation after its formation and stabilization, fibrin clots,
formed as for the permeability evaluation, were perfused with
a Tris buffer with 0.2μmol L-1 rtPA (Boehringer Ingelheim).
D-dimer levels were measured every 20min in the effluent
using an ELISA kit (American Diagnostica). The experiment
was stopped, usually after 80–120min, when the fibrin gel
collapsed under the pressure. The maximum rate of increase
in D-dimer levels (D–Drate) in the buffer and maximum
D-dimer concentrations (D–Dmax) were analyzed [19].
2.7. Genotyping. Factor V Leiden (FV Leiden), prothrombin
20210A, factor XIII Val34Leu (FXIII Val34Leu), and
α-fibrinogen Thr312Ala polymorphisms were determined
by the polymerase chain reaction followed by restriction
fragment length polymorphism analysis, as previously
described [10].
2.8. Statistical Analysis. The study was powered to have a 90%
chance of detecting a 10% difference in Ks, a key measure of
clot properties, using a p value of 0.05, based on the values of
Ks from a published article [20]. To demonstrate such a dif-
ference, or a greater one, 30 patients or more were required in
each group.
All calculations were done with STATISTICA 12.0 soft-
ware (StatSoft, Poland).
Categorical variables are presented as numbers and per-
centages. Continuous variables are expressed as mean ±
standard deviation or median and interquartile range
(IQR), as appropriate. The Shapiro–Wilk test was used to
assess normality and Levene’s test was taken to check equal-
ity of variances. Differences between groups were compared
using either the Welch’s t-test or the Mann–Whitney U test,
depending on the equality of variances for normally distrib-
uted variables. Categorical variables were analyzed using
either the chi2 test or Fisher’s exact test. We used Kruskal-
Wallis ANOVA with post hoc Tuckey test to investigate
intergroup differences between multiple groups. Pearson’s
correlation coefficient (Pearson’s r) or Spearman’s rank
correlation coefficient were calculated to assess the linear
correlations between variables with a normal or nonnor-
mal distribution, respectively. Associations between the
variables were expressed as odds ratios with 95% confi-
dence intervals. Two-sided p values <0.05 were considered
statistically significant.
3. Results
3.1. Participants’ Characteristics. As shown in Table 1, there
were no intergroup differences regarding demographic vari-
ables, smoking status, family history of VTE, obesity, and
diabetes mellitus (Table 1). In the contraception-related
VTE group, the prevalence of arterial hypertension was lower
than in both unprovoked VTE and control groups. In terms
of routine laboratory tests, compared with the control group,
women following unprovoked VTE had slightly higher tri-
glycerides (TG) and increased low-density lipoprotein cho-
lesterol (LDL-C). Other laboratory investigations, including
fibrinogen, were similar in the 3 groups (Table 1).
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Analysis of the genetic polymorphisms revealed similar
carrier frequencies in all groups, except for a higher preva-
lence of FXIII 34Leu allele carriers in the contraception-
related VTE group, compared with the two remaining groups
(Table 1). Factor V Leiden mutation tended to occur more
often in the contraception-related VTE group than in the
unprovoked group (Table 1); however, the difference did
not reach the level of statistical significance.
3.2. Thrombotic and Fibrinolysis Markers. Peak thrombin
generation was higher both in the contraception-related
VTE group (+63.8%) and in the unprovoked VTE group
(+36.7%) contrary to in the control group (Figure 1(a)).
Moreover, women with contraception-related VTE had
19.8% higher peak thrombin generation when compared
with unprovoked VTE. No intergroup differences in plas-
minogen and α2-antiplasmin were observed (Table 1).
Plasma PAI-1 was higher by 14.9% in the contraception-
related VTE group and by 17.8% in the unprovoked
VTE group when compared with the control group
(Figure 1(b)).
3.3. Fibrin Clot Properties.Women from both contraception-
related and unprovoked VTE group had lower Ks when com-
pared with the control group (8.6% and 13.4%, respectively;
Figure 2(a)) indicating the formation of more compact fibrin
networks. There was no association between Ks and throm-
bin generation in either group.
Both contraception-related and unprovoked VTE groups
were characterized by shorter lag phase when compared with
the controls (by -8.8% and -20.4%, respectively). Contrary to
the unprovoked VTE group, women with contraception-
related VTE had longer lag phase (by +8.6%). No intergroup
differences in ΔAbsmax were observed.
Regarding fibrinolysis, both contraception-related and
unprovoked VTE groups showed longer CLT when com-
pared with the control group (by 11.5% and 14.5%, respec-
tively; Figure 2(c)). CLT was positively correlated with PAI-
1 Ag in both contraception-related and unprovoked groups
(r = 0:63, p = 0:005 and r = 0:68, p = 0:007, respectively).
CLT tended to be positively associated with plasminogen
(r = 0:74, p = 0:064 and r = 0:83, p = 0:072, respectively)
and antiplasmin (r = 0:51, p = 0:061 and r = 0:48, p = 0:070,
respectively).
Table 1: Characteristics of the studied groups.
Variable Contraception-related VTE (n = 48) Unprovoked VTE (n = 48) Control group (n = 48) p value
Age (years) 32:6 ± 8:0 32:4 ± 6:6 32:9 ± 8:0 0.9
BMI (kg/m2) 27:4 ± 2:3 27:2 ± 3:4 25:9 ± 3:1 0.06
Cigarette smoking, n (%) 21 (44) 15 (32) 16 (33) 0.4
Family history of VTE, n (%) 11 (23) 9 (19) 4 (8) 0.14
Obesity, n (%) 11 (23) 10 (21) 5 (10) 0.33
Arterial hypertension, n (%) 4 (8) 14 (29) 11 (23) 0.03
Diabetes mellitus, n (%) 1 (2) 2 (4) 3 (6) 0.59
Laboratory parameters
Fibrinogen (g/L) 2.89 (2.48-3.73) 2.90 (2.36-3.290) 2.76 (2.34-3.42) 0.77
INR 0:98 ± 0:08 0:97 ± 0:16 0:97 ± 0:15 0.89
Creatinine (μmol/L) 61:5 ± 10:73 63:5 ± 7:30 63:9 ± 7:05 0.36
Glucose (mmol/L) 4.95 (4.60-5.45) 4.80 (4.45-5.35) 5.20 (4.80-5.85) 0.60
TG (mmol/L) 1.25 (0.77-1.73) 1.31 (0.85-1.85) 1.18 (0.82-1.61) 0.04
TC (mmol/L) 5:12 ± 1:24 5:35 ± 0:98 4:85 ± 0:89 0.07
HDL-C (mmol/L) 1:51 ± 0:47 1:38 ± 0:38 1:38 ± 0:35 0.20
LDL-C (mmol/L) 3:00 ± 0:92 3:32 ± 0:85 2:92 ± 0:71 0.04
hsCRP (mg/L) 1.18 (0.93-1.78) 1.79 (1.15-2.37) 1.51 (0.91-2.25) 0.11
D-dimer (ng/mL) 272 (212-359) 279 (219-341) 247 (210-300) 0.10
Plasminogen (%) 109:5 ± 13:93 107:4 ± 13:94 108:8 ± 15:77 0.78
α2-Antiplasmin 99:60 ± 10:42 102:38 ± 9:13 103:6 ± 9:09 0.06
Genetic polymorphisms, n (%)
Factor XIII Val34Leu 23 (48) 16 (33) 10 (21) 0.04
α-Fibrinogen Thr312Ala 21 (44) 22 (46) 14 (29) 0.30
Factor V Leiden 8 (17) 7 (15) 2 (4) 0.13
Prothrombin 20210A mutation 2 (4) 2 (4) 2 (4) 1.00
Data are shown as mean ± standard deviation, median (interquartile range) or number (percentage). Abbreviations: HDL-C, high-density lipoprotein
cholesterol; hsCRP, high-sensitivity C-reactive protein; INR, international normalized ratio; LDL-C, low-density lipoprotein cholesterol; TC, total
cholesterol; TG, triglycerides; and VTE, venous thromboembolism.
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As shown in Figure 2(d), the D-Dmax was lower by 8.6%
in the contraception-related VTE group when compared
with the unprovoked VTE group. Contrary to the control
group, both contraception-related and unprovoked VTE
groups were characterized by slightly lower D-Drate (by
7.1% and 5.6%, respectively, Figure 2(e)). Regarding types
of contraception, we observed 13.2% lower D-Drate (post
hoc Tuckey p = 0:006) and 9.3% higher D-Dmax (post hoc
Tuckey p = 0:047) in women with VTE provoked by oral con-
traceptives with 2nd-generation progesteron when compared
with transdermal contraception-provoked VTE (Table 2).
No other differences in the parameters measured were
observed in relation to the type of contraception used before
VTE event (Table 2).
4. Discussion
The current study shows that women who experienced the
first contraception-related episode of VTE, compared with
controls, demonstrate increased thrombin generation and
prothrombotic plasma fibrin clot phenotype, evidenced by
faster formation of denser fiber networks and reduced clot
susceptibility to lysis. We found no differences in most pro-
thrombotic variables between women following VTE related
to hormonal contraception and those after unprovoked VTE,
apart from slightly lower maximumD-dimer levels measured
during lytic clot degradation and higher peak thrombin
generation and longer lag phase in the first group. Our
study suggests that women with both contraception-
related and unprovoked VTE may remain at a similarly
increased risk of a subsequent thrombotic event, which
might imply benefits from longer anticoagulation in a sub-
set of those patients.
There is a controversy whether contraception-related
first VTE can be classified as either unprovoked VTE, thus
regarding hormonal therapy as a “weak” risk factor, or pro-
voked VTE [11, 12]. It has been reported that in young
women with a first episode of VTE, no significant association
was found between exposure to CHCs and the incidence of
recurrent VTE after adjustment for age or after restricting
the analysis to major unprovoked VTE: incidence rate of
recurrence 17.9/1,000/year (95% confidence interval (CI):
9.6-33.2) in women with CHC as compared with
17.6/1,000/year (95% CI: 6.6-47) with an incidence ratio of
0.7 (95% CI: 0.2-2.4, p = 0:59) [21–25]. Other studies
reported that the risk of VTE recurrence after anticoagulant
therapy for the first unprovoked VTE episode is comparable
between women on or off estrogen containing CHCs and
HRT [24, 26]. It has been reported that the risk of recurrent
VTE is similar in estrogen users at the time of their first
VTE episode (9.7 per 1,000 patient-years; 95% CI: 4.3–21.5)
and nonusers (16.2; 95% CI: 8.7–30.2) [27]. Moreover, other
study showed an incidence rate for recurrent VTE of 5.1% for
the first year, 7.8% for the first 2 years, 14.2% for the first 5
years, and 28.6% for 10 years in CHCs users, which is a high
risk of recurrence given the age of the patients (median 25.5
years) [23, 24, 28].
It has been reported that women at reproductive age, tak-
ing CHCs, are characterized by a prothrombotic fibrin clot
phenotype with prolonged lysis, and that discontinuation of
CHCs was associated with shortened CLT and increased Ks
[4]. The current study expands previous findings by compre-
hensive evaluation of plasma clot structure and function in
women with contraception-related VTE. A similarly pro-
thrombic phenotype reflected by reduced Ks and prolonged
CLT was observed in both VTE groups, which is a novel
and somewhat intriguing observation. We expected more
favorable clot features in those women compared with well-
matched comparators after unprovoked VTE. These findings
suggest that solely young and middle age, relatively healthy
women with a more prothrombotic state could be prone to
VTE if they take contraceptives. It might be speculated that
there is a subset of women at risk of VTE while taking contra-
ceptives (similarly to those with prior VTE) who could be
determined using some coagulation parameters. However,
since the variables tested in this study were not measured
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Figure 1: Comparison of peak thrombin (a) and plasminogen activator inhibitor-1 (PAI-1, (b)) in 3 studied groups; ((A) the contraception-
related group, (B) the unprovoked VTE group, and (C) the control group).
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prior to contraceptives and prior to VTE while on COCs, this
hypothesis requires corroboration. Furthermore, lower Ks
with prolonged CLT accompanied by reduced D-Drate, that
was observed in our study, have been recently demonstrated
to predict the VTE recurrence [8, 19]; therefore, it might be
speculated that VTE recurrences in women following
contraception-related VTE could be at least in part driven
by the unfavorable clot properties. It has been shown that
subjects with recurrent DVT during follow-up were charac-
terized by slightly lower plasma clot permeability and 15%
longer CLTmeasured at 3 months since the index event com-
pared with the controls [19].
(A) (B) (C)
5,5
6,0
6,5
7,0
7,5
8,0
8,5
9,0
9,5
10,0
K s
 (1
0−
9 c
m
2 )
p = 0.04
p < 0.0001
(a)
(A) (B) (C)
32
34
36
38
40
42
44
46
48
50
52
54
56
58
La
g 
ph
as
e (
s)
p < 0.0001
p < 0.0001p = 0.002
(b)
(A) (B) (C)
CL
T 
(m
in
)
60
70
80
90
100
110
120
130
p = 0.04
p = 0.005
(c)
(A) (B) (C)
D
-D
m
ax
 (m
g/
L)
3,2
3,4
3,6
3,8
4,0
4,2
4,4
4,6
4,8
5,0
5,2
5,4
p = 0.006
(d)
(A) (B) (C)
D
-D
ra
te
 (m
g/
L/
m
in
)
0,062
0,064
0,066
0,068
0,070
0,072
0,074
0,076
0,078
0,080
0,082
0,084
0,086
p = 0.0005
p = 0.03
(e)
Figure 2: Comparison of fibrin clot permeability coefficient (Ks, (a)), lag phase (b), clot lysis time (CLT, (c)), maximum D-dimer levels
in the lysis assay (D-Dmax, (d)), and maximum rate of increase in D-dimer levels in the lysis assay (D-Drate, (e)) in the 3 studied
groups. Data are shown as mean and standard deviation (SD) ((A) the contraception-related group, (B) the unprovoked VTE group, and
(c) the control group).
6 Disease Markers
Our study also showed less efficient fibrinolysis in part
associated with increased PAI-1:Ag concentration in both
VTE groups, which agrees with previous reports [20]. Asso-
ciation of hypofibrinolysis with VTE reflects to some extent
the relationship of elevated PAI-1 and the development of
VTE [18]. It is known that PAI-1 is positively associated with
BMI [15]. In our study, there were no differences in BMI
between both VTE groups; therefore, the current intergroup
differences in PAI-1 cannot be explained by differences
in BMI.
An interesting finding in our study is increased throm-
bin generation in young and middle-aged women follow-
ing a few months from the contraception-related VTE
group. Interestingly, peak thrombin generated in the
contraception-related VTE group was higher to that found
in well-matched women following unprovoked VTE.
Increased peak thrombin leads to the disturbed balance
of pro- and anticoagulant mechanisms during thrombin
generation reflected by enhanced prothrombin conversion
and reduced thrombin inactivation [29, 30].
Unexpectedly, we observed a higher prevalence of FXIII
Val34Leu carriers in women following contraception-
related VTE. It is known that this common polymorphism
results in the formation of a clot with smaller pores and thin-
ner fibers largely due to faster FXIII activation [31]. Meta-
analysis of 11 studies has confirmed that this common FXIII
polymorphism can have a moderate protective effect against
VTE [32, 33]. Based on the current findings, it might be spec-
ulated that the 34Leu FXIII allele could contribute to the risk
of contraception-related VTE in part through unfavorable
alterations to clot properties enhanced by hormones. The
present observation suggesting the role of Val34Leu allele
on contraception-related VTE risk warrants further studies.
It has been convincingly shown that contraceptives with
levonorgestrel (the second-generation progestogen) carry a
2- to 4-fold increased risk of VTE, which is the lowest among
all generations of COCs [34]. The use of the third-generation
progestogens, represented by gestoden, desogestrel, and nor-
gestimate, is associated with 3- to 8-fold increased risk of
VTE when compared with nonusers [11]. There is evidence
that transdermal patches, containing 15-20μg of ethinyles-
tradiol per day combined with norgestimate, are associated
with a 2-fold increased risk of VTE and appear to be safer
than oral preparations [34]. Our study showed that in con-
trast to women with transdermal contraception-related
VTE, participants with contraception-related VTE provoked
by oral 2nd-generation progestogens have more unfavorable
clot properties. It might be speculated that women with the
“worse” clot properties are prone to develop VTE while using
COCs containing-second generation progestogens, and
women with less prothrombotic clot features could be to
some extent “resistant” to such adverse events compared
with other forms of COCs. However, low numbers of patients
in the subgroup analysis render these observations prelimi-
nary and they should be treated with extreme caution.
Our study had several limitations. First, the sample size
was relatively small but the groups were well-matched and
the study was adequately powered. Second, fibrin clot param-
eters were only analyzed once, shortly after thromboembolic
event, and it is unknown whether prothrombotic features
reported here persisted. Third, some potential modulators
of clot properties, for example TAFI and C3 protein, were
unmeasured in this study. Subsequently, women who took
COCs to decrease the intensity of premenstrual syndrome
(PMS), androgenization described as hirsutism or acne and
menstrual bleeding disorders which are present in polycystic
ovary syndrome associated with increased risk of VTE [35],
were also ineligible. Therefore, the results we have reported
in our study, cannot be easily extrapolated to such women.
Fourth, in both VTE groups there were more FV Leiden
carriers as compared to the control group, although this
difference was not significant. Moreover, contrary to the con-
trols, in the VTE group, we observed higher frequency of
FXIIIVal34Leu which has affected clot formation and clot
structure. Finally, long-term follow-up was beyond the scope
of the present study so it remains to be established whether
the prothrombotic features are risk factors for VTE recur-
rence in women following contraception-related VTE, but
given recent evidence from a cohort study suggesting that
the fibrin clot phenotype has a predictive value of recurrent
VTE [8].
5. Conclusion
Our study showed that women who experienced
contraception-related VTE exhibit denser fibrin clot
formation and impaired clot lysis associated with increased
PAI-1:Ag concentration. It might be considered to prolong
Table 2: Comparison of fibrin clot properties in the contraception-related VTE group regarding type of contraception.
Variable
Type of contraception
p
CHC 2nd (n = 16) CHC 3rd (n = 16) Transdermal (n = 16)
Ks (10
–9cm2) 6:6 ± 1:1 7:2 ± 1:3 7:3 ± 1:3 0.36
Lag phase (s) 41:5 ± 7:1 42:1 ± 5:8 43:0 ± 7:0 0.90
ΔAbsmax (405 nm) 0:82 ± 0:1 0:81 ± 0:1 0:75 ± 0:1 0.26
CLT (min) 86 ± 18:1 90 ± 13:8 93:8 ± 27:8 0.63
D-Drate (mg/L/min) 0:068 ± 0:006 0:070 ± 0:004 0:077 ± 0:009 0.007
D-Dmax (mg/L
A) 4.0 (3.4-4.1) 3.70 (3.4-4.2) 3.66 (3.3-3.7) 0.05
Data are shown as mean ± standard deviation or median (interquartile range). Abbreviations: CHC, combined hormonal contraception containing estrogen
plus 2nd- or 3rd-generation progesterone; ΔAbsmax, maximum absorbance at the plateau phase; CLT, clot lysis time; D-Dmax, maximum D-dimer levels in
the lysis assay; D-Drate, maximum rate of increase in D-dimer levels in the lysis assay; Ks, fibrin clot permeability coefficient.
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anticoagulant therapy in women with contraception-related
VTE if they display prothrombotic clot features after 3
months of treatment. Our study showing enhanced thrombin
generation, reflected by increased peak thrombin, and
impaired fibrinolysis associated with PAI-1 in women fol-
lowing conception-related VTE could have practical implica-
tions. The laboratory markers presented here could be of
value in identifying the women at higher risk of VTE.
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